Drug & intervention

regorafenib

RxCUI 1312397

Clinical trials11
Recruiting1
Related conditions20
Synonyms2

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

11 shown
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNCT06047379 · 2023-11-01
RECRUITING
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid TumorsNCT07857135 · 2026-10-03
NOT_YET_RECRUITING
A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal CancerNCT07137390 · 2025-09-03
WITHDRAWN
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension StudyNCT05600309 · 2022-06-14
COMPLETED
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)NCT05064059 · 2021-11-10
COMPLETED
Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)NCT04776148 · 2021-03-29
COMPLETED
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialNCT03878524 · 2020-04-01
TERMINATED
Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung CancerNCT03520842 · 2018-08-14
COMPLETED
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibNCT02955940 · 2016-11-30
ACTIVE_NOT_RECRUITING
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic AlterationsNCT02795156 · 2016-09-28
COMPLETED
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine TumorsNCT02259725 · 2016-08-16
COMPLETED

Conditions being studied

Colorectal Cancer4Urothelial Carcinoma2Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Advanced/Metastatic Solid Tumors1Anatomic Stage IV Breast Cancer AJCC v81Anemia1Ann Arbor Stage III Hodgkin Lymphoma1Ann Arbor Stage III Non-Hodgkin Lymphoma1Ann Arbor Stage IV Hodgkin Lymphoma1Ann Arbor Stage IV Non-Hodgkin Lymphoma1Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative1Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Brain Metastases, Adult1Breast Cancer1Castration-Resistant Prostate Carcinoma1Cervical Cancer1Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Colorectal Cancer (CRC)1Colorectal Neoplasms1Diffuse Astrocytoma, IDH-Mutant1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.